标题
New treatment modalities in advanced thyroid cancer
作者
关键词
-
出版物
ANNALS OF ONCOLOGY
Volume 23, Issue 1, Pages 10-18
出版商
Oxford University Press (OUP)
发表日期
2011-04-08
DOI
10.1093/annonc/mdr117
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- The First-in-Human Study of the Hydrogen Sulfate (Hyd-Sulfate) Capsule of the MEK1/2 Inhibitor AZD6244 (ARRY-142886): A Phase I Open-Label Multicenter Trial in Patients with Advanced Cancer
- (2010) U. Banerji et al. CLINICAL CANCER RESEARCH
- Vandetanib (100 mg) in Patients with Locally Advanced or Metastatic Hereditary Medullary Thyroid Cancer
- (2010) Bruce G. Robinson et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Phase II Clinical Trial of Sorafenib in Metastatic Medullary Thyroid Cancer
- (2010) Elaine T. Lam et al. JOURNAL OF CLINICAL ONCOLOGY
- Vandetanib for the Treatment of Patients With Locally Advanced or Metastatic Hereditary Medullary Thyroid Cancer
- (2010) Samuel A. Wells et al. JOURNAL OF CLINICAL ONCOLOGY
- Role of MAPK pathway oncoproteins in thyroid cancer pathogenesis and as drug targets
- (2009) Jeffrey A Knauf et al. CURRENT OPINION IN CELL BIOLOGY
- Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma
- (2009) Hendrieke Hoftijzer et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Gene Therapy in Thyroid Cancer
- (2009) C. Spitzweg HORMONE AND METABOLIC RESEARCH
- Gastrosplenic Fistula From Hodgkin's Lymphoma
- (2009) Carolyn D. Seib et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Study of Safety and Efficacy of Motesanib in Patients With Progressive or Symptomatic, Advanced or Metastatic Medullary Thyroid Cancer
- (2009) Martin J. Schlumberger et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Trial of Sorafenib in Metastatic Thyroid Cancer
- (2009) Richard T. Kloos et al. JOURNAL OF CLINICAL ONCOLOGY
- Association ofPTENgene methylation with genetic alterations in the phosphatidylinositol 3-kinase/AKT signaling pathway in thyroid tumors
- (2008) Peng Hou et al. CANCER
- Dendritic Cell Vaccination with Xenogenic Polypeptide Hormone Induces Tumor Rejection in Neuroendocrine Cancer
- (2008) C. Papewalis et al. CLINICAL CANCER RESEARCH
- Multi-Kinase Inhibitor E7080 Suppresses Lymph Node and Lung Metastases of Human Mammary Breast Tumor MDA-MB-231 via Inhibition of Vascular Endothelial Growth Factor-Receptor (VEGF-R) 2 and VEGF-R3 Kinase
- (2008) J. Matsui et al. CLINICAL CANCER RESEARCH
- Combined immunostaining with galectin-3, fibronectin-1, CITED-1, Hector Battifora mesothelial-1, cytokeratin-19, peroxisome proliferator-activated receptor-γ, and sodium/iodide symporter antibodies for the differential diagnosis of non-medullary thyroid carcinoma
- (2008) Ying Y Liu et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Lack of Therapeutic Effect of the Histone Deacetylase Inhibitor Vorinostat in Patients with Metastatic Radioiodine-Refractory Thyroid Carcinoma
- (2008) Jennifer A. Woyach et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Axitinib Is an Active Treatment for All Histologic Subtypes of Advanced Thyroid Cancer: Results From a Phase II Study
- (2008) Ezra E.W. Cohen et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Trial of Sorafenib in Advanced Thyroid Cancer
- (2008) Vandana Gupta-Abramson et al. JOURNAL OF CLINICAL ONCOLOGY
- Motesanib Diphosphate in Progressive Differentiated Thyroid Cancer
- (2008) Steven I. Sherman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Rosiglitazone Effect on Radioiodine Uptake in Thyroid Carcinoma Patients with High Thyroglobulin but Negative Total Body Scan: A Correlation with the Expression of Peroxisome Proliferator–Activated Receptor-Gamma
- (2008) Supatporn Tepmongkol et al. THYROID
- Clinical implications of BRAF mutation in thyroid carcinoma
- (2008) Efisio Puxeddu et al. TRENDS IN ENDOCRINOLOGY AND METABOLISM
- A Phase II Study of Gefitinib in Patients with Advanced Thyroid Cancer
- (2007) Nathan A. Pennell et al. THYROID
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started